Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
1,858 SEK | +3,22 % | -1,48 % | -53,67 % |
14.04. | Syrien: Irans Angriff gegen Israel ist dessen 'legitimes Recht' | DP |
02.04. | Iranische Generäle in Syrien getötet - Wie reagiert Teheran? | DP |
Kurzporträt
Mitarbeiterzahl: 23
Umsatz nach Geschäftsbereich
SEK in Millionen | 2021 | Gewichtung | 2022 | Gewichtung | Delta |
---|---|---|---|---|---|
Rare Diesease Patients Innovative Treatments
100,0
%
| 10 | 100,0 % | 15 | 100,0 % | +45,86 % |
Umsatz je Region
SEK in Millionen | 2021 | Gewichtung | 2022 | Gewichtung | Delta |
---|---|---|---|---|---|
Other European Countries
75,4
%
| 8 | 76,1 % | 12 | 75,4 % | +44,49 % |
Americas
24,6
%
| 3 | 23,9 % | 4 | 24,6 % | +50,16 % |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Founder | 66 | 01.01.11 | |
Thomas Feldthus
CEO | Chief Executive Officer | 64 | 01.01.11 |
Jørgen Drejer
FOU | Founder | 69 | 01.01.11 |
Anita Milland
DFI | Director of Finance/CFO | 56 | 01.01.14 |
Karin Nielsen
CTO | Chief Tech/Sci/R&D Officer | 54 | - |
Chief Tech/Sci/R&D Officer | 65 | 01.05.20 | |
Corporate Officer/Principal | 52 | - |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Jørgen Drejer
FOU | Founder | 69 | 01.01.11 |
Director/Board Member | 66 | 01.01.15 | |
Anna Ljung
BRD | Director/Board Member | 44 | 19.01.18 |
Director/Board Member | 58 | 01.01.23 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 132 529 086 | 80 887 377 ( 61,03 %) | 0 | 61,03 % |
Unternehmenskontakt
Konzerngesellschaften
Name | Kategorie und Branche |
---|---|
Saniona A/S
Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The private company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders. |
Miscellaneous Commercial Services
|
Sektor
Umsatz je Region
Jahresgewinne - Abweichungsrate
% 1. Jan. | Kap. | |
---|---|---|
-53,67 % | 18,36 Mio. | |
-2,31 % | 103 Mrd. | |
+0,56 % | 95,71 Mrd. | |
+1,69 % | 22,02 Mrd. | |
-17,37 % | 20,9 Mrd. | |
-9,30 % | 17,85 Mrd. | |
-41,01 % | 16,21 Mrd. | |
-14,85 % | 15,52 Mrd. | |
+3,21 % | 13,86 Mrd. | |
+33,54 % | 12,04 Mrd. |
- Börse
- Aktien
- A110VV Aktie
- Unternehmen SANA AB